MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
... The most common side effects (vs placebo) were flatulence 11.3% (vs 19.7%), headache 9.7% (vs 9.2%), abdominal pain 7.2% (vs 10.1%), and rectal tenesmus 7.2% (vs 8.8%). Full prescribing information may be found at http://salix.com/assets/pdf/xifaxan/XifaxanPI.pdf . ...Salix Pharmaceuticals Previews Digestive Disease Week 2007
... The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %) and rectal tenesmus 7.2% (vs. 8.8%). MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) ...